Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sangamo Biosciences ( (SGMO) ) has shared an announcement.
Sangamo Therapeutics faced legal challenges over a stock increase amendment, but the Delaware Court of Chancery validated the voting process, clearing uncertainties. Meanwhile, in collaboration with Pfizer, Sangamo presented promising results from the Phase 3 AFFINE trial for a gene therapy targeting hemophilia A, showing significant reductions in bleeding rates. These developments are pivotal for investors tracking Sangamo’s strategic moves and the broader gene therapy market.
See more insights into SGMO stock on TipRanks’ Stock Analysis page.